cagrilintide
Sponsor NOVO Nordisk A S · listed as NVO
cagrilintide is a drug asset sponsored by NOVO Nordisk A S, listed as NVO. CSA tracks 7 forward catalysts for it — the nearest is a readout expected Mar 1, 2027 (day precision, medium confidence), tied to trial NCT07011667. That trial is in Phase 3 and currently active not recruiting, studying Obesity. It appears across 11 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for cagrilintide
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2027-03-01 | READOUT | medium | NCT07011667 |
| 2027-05-11 | READOUT | medium | NCT07220642 |
| 2027-05-12 | READOUT | medium | NCT07220759 |
| 2027-05-18 | READOUT | medium | NCT07745504 |
| 2027-06-09 | READOUT | medium | NCT07817251 |
| 2027-09-01 | READOUT | medium | NCT05669755 |
| 2028-02-23 | READOUT | medium | NCT07564414 |
Trials for cagrilintide in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05567796 | Phase 3 | Active, not recruiting | 2024-10-30 | Experimental | Novo Nordisk A/S | Obesity |
| NCT07011667 catalyst | Phase 3 | Active, not recruiting | 2027-03-01 | Experimental | Novo Nordisk A/S | Obesity |
| NCT07220642 catalyst | Phase 3 | Active, not recruiting | 2027-05-11 | Experimental | Novo Nordisk A/S | Obesity; Overweight |
| NCT07220759 catalyst | Phase 3 | Active, not recruiting | 2027-05-12 | Experimental | Novo Nordisk A/S | Overweight; Obesity; Type 2 Diabetes |
| NCT07745504 catalyst | Phase 3 | Recruiting | 2027-05-18 | Experimental | Novo Nordisk A/S | Overweight; Obesity |
| NCT07817251 catalyst | Phase 3 | Recruiting | 2027-06-09 | Experimental | Novo Nordisk A/S | Diabetes Mellitus, Type 2 |
| NCT05669755 catalyst | Phase 3 | Active, not recruiting | 2027-09-01 | Experimental | Novo Nordisk A/S | Cardiovascular Disease |
| NCT07564414 catalyst | Phase 3 | Recruiting | 2028-02-23 | Experimental | Novo Nordisk A/S | Obesity; Type 2 Diabetes |
| NCT06780449 | Phase 3 | Active, not recruiting | 2028-08-28 | Experimental | Novo Nordisk A/S | Obesity |
| NCT07282613 | Phase 3 | Recruiting | 2029-09-07 | Experimental | Novo Nordisk A/S | Diabetes Mellitus, Type 2 |
| NCT07253285 | Phase 3 | Recruiting | 2030-03-20 | Experimental | Novo Nordisk A/S | Overweight; Obesity |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More NVO catalysts